TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15944868
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch for 36 hours
Study: 9498887
Drug: 11.25 mg
Normalized name: phentermine 11.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11.25 mg midazolam
Study: 8147070
Drug: Diltiazem (D)
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem (D) - 300 micrograms/kg bolus and 5.4 micrograms/kg/min continuous infusion
Study: 8147070
Drug: Nisoldipine (N)
Normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nisoldipine (N) - 5 micrograms/kg bolus and 0.2 micrograms/kg/min continuous infusion
Study: 3168559
Drug: Peroral intestinal
Normalized name: pork intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peroral intestinal cleansing with 1.5 l cold electrolyte solution
Study: 3168559
Drug: Rectal lavaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal lavaging
Study: 11903525
Drug: Intravenous valproate
Normalized name: valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous valproate 500 mg
Study: 11903525
Drug: Intramuscular dihydroergotamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular dihydroergotamine 1 mg with metoclopramide 10 mg
Study: 11903525
Drug: Intramuscular dihydroergotamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular dihydroergotamine
Study: 25064429
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both BSSO and Le Fort I
Study: 22801294
Drug: Pramipexole extended-release
Normalized name: pramipexole Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole extended-release (ER) once daily for 12 weeks, titrated to a maximum daily dose of 4.5 mg
Study: 22801294
Drug: Pramipexole immediate-release
Normalized name: pramipexole Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole immediate-release (IR) 2 to 3 times daily for 12 weeks, titrated to a maximum daily dose of 4.5 mg
Study: 22801294
Drug: Both ER
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both ER and IR formulations
Study: 20530645
Drug: Constraint-induced movement
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint-induced movement therapy (affected arm trained for 3 hours/day, non-affected arm restricted for 10 hours/day for two weeks)
Study: 12224977
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% imiquimod cream applied once daily for 7 days per week for 6 weeks
Study: 12224977
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% imiquimod cream applied once daily for 7 days per week for 12 weeks
Study: 12224977
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream (placebo) applied once daily for 3, 5, or 7 days per week, or twice daily for 7 days per week for 12 weeks
Study: 7978560
Drug: Nebulized albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized albuterol treatments (1990)
Study: 4577015
Drug: Extradural corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extradural corticosteroid injection
Study: 31722314
Drug: Ropinirole hydrochloride
Normalized name: Ropinirole Hydrochloride
DrugBank: Ropinirole (DB00268)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ropinirole hydrochloride extended-release tablets
Study: 11128567
Drug: Metoclopramide (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (1.5 mg/kg, i.v.)
Study: 26303665
Drug: Electrical stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical stimulation in the anterior limbs of the internal capsule (ALIC)
Study: 20028444
Drug: Latanoprost 0.005%
Normalized name: LATANOPROST 0.005% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost 0.005% (50 microg/mL) ophthalmic solution applied nightly to eyelid margins
Study: 20028444
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving triamcinolone acetonide (TAC) injections
Study: 17894912
Drug: Ketamine (intraoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (intraoperative bolus of 0.15 mg kg‐1, followed by 0.5 mg per morphine 1 mg in a patient‐controlled analgesia device)
Study: 12190090
Drug: Eradication therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradication therapy with omeprazole for 3 months
Study: 12190090
Drug: Placebo antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo antibiotics with omeprazole for 3 months
Study: 12190090
Drug: Eradication therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradication therapy in patients with antrum-predominant gastritis
Study: 8625221
Drug: Octreotide 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 150 micrograms subcutaneously three times daily
Study: 23649906
Drug: Acidic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acidic saline (pH 3.3) injection
Study: 23649906
Drug: Regular isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular isotonic saline injection
Study: 23649906
Drug: Repeated injection
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated injection of acidic saline
Study: 23649906
Drug: Injections (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injections (both acidic and regular saline)
Study: 20220040
Drug: L-DOPS +
Normalized name: L-DOPS
DrugBank: Droxidopa (DB06262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-DOPS + Placebo (PLA)
Study: 20220040
Drug: L-DOPS +
Normalized name: L-DOPS
DrugBank: Droxidopa (DB06262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-DOPS + Entacapone (ENT)
Study: 20220040
Drug: L-DOPS +
Normalized name: L-DOPS
DrugBank: Droxidopa (DB06262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-DOPS + Carbidopa (CAR)
Study: 19451574
Drug: Pulse cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse cyclophosphamide, 15 mg/kg every 2 to 3 weeks
Study: 19451574
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral cyclophosphamide, 2 mg/kg per day
Study: 11355559
Drug: Albendazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (400 mg twice a day, in 3 cycles of 6 weeks with 2 weeks between cycles)
Study: 2506091
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy (twice daily for 6 months)
Study: 2506091
Drug: Glibenclamide and
Normalized name: Glibenclamide and metformin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide and metformin combination therapy (for 6 months)
Study: 25714579
Drug: Vitamin E,
Normalized name: GRx Vitamin E, topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin E, Metformin, or Placebo (Control) for 96 weeks
Study: 15006954
Drug: Moxifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (400 mg qd for 5 days)
Study: 15006954
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (amoxicillin [500 mg tid for 7 days], clarithromycin [500 mg bid for 7 days], or cefuroxime‐axetil [250 mg bid for 7 days])
Study: 9422470
Drug: G‐CSF 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF 10 microg/kg/day + GM‐CSF 5 microg/kg/day (arm II)
Study: 9422470
Drug: G‐CSF 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF 10 microg/kg/day alone (arm I)
Study: 8486084
Drug: Propofol (0.2‐0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (0.2‐0.6 mg/kg)
Study: 3322376
Drug: Epostane (progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epostane (progesterone synthesis inhibitor)
Study: 25907821
Drug: Optimized medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized medical treatment of COPD
Study: 23294275
Drug: Rivaroxaban (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (10 mg) in subjects with mild hepatic impairment
Study: 23294275
Drug: Rivaroxaban (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (10 mg) in subjects with moderate hepatic impairment
Study: 18068522
Drug: Aspirin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (75 mg enteric-coated tablet per day)
Study: 18068522
Drug: Control (aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (aspirin avoidance)
Study: 16595222
Drug: rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone (4 mg twice daily) and clomiphene citrate (100 mg from the third day for 5 days)
Study: 16595222
Drug: metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin (500 mg three times daily) and clomiphene citrate (100 mg from the third day for 5 days)
Study: 8613267
Drug: Brain natriuretic
Normalized name: Brain natriuretic peptide
DrugBank: .gamma.-brain natriuretic peptide (DB19026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brain natriuretic peptide (BNP) infusion
Study: 8613267
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ANP and BNP infusions
Study: 1748538
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg intravenous metronidazole
Study: 1748538
Drug: 1.0 gm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 gm intravenous metronidazole
Study: 1748538
Drug: 2.0 gm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 gm intravenous metronidazole
Study: 1748538
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of metronidazole (1.0 gm and 2.0 gm)
Study: 6412738
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of steroids and SCG
Study: 21041836
Drug: Fluoridated artificial
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoridated artificial saliva (FS) at 1500 ppm fluoride treatment alone
Study: 21041836
Drug: Fluoridated artificial
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoridated artificial saliva (FS) at 1500 ppm fluoride treatment combined with thermocycling (FS + Th)
Study: 20430500
Drug: Folate (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folate (15 mg/d)
Study: 20430500
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of folate (15 mg/d) and methylcobalamin (500 mug after each hemodialysis treatment 3 times weekly)
Study: 19186852
Drug: NaF group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaF group (1450 mg/L sodium fluoride dentifrice)
Study: 19186852
Drug: MFP group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: MFP group (1450 mg/L sodium monofluorophosphate dentifrice)
Study: 9485231
Drug: Epsilon-aminocaproic acid
Normalized name: Epsilon-Aminocaproic acid
DrugBank: Aminocaproic acid (DB00513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epsilon-aminocaproic acid (15-g bolus + infusion of 1 g/h)
Study: 9485231
Drug: High-dose tranexamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose tranexamic acid (10-g bolus + placebo infusion)
Study: 2147014
Drug: Monophasic preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monophasic preparation containing ethinylestradiol and desogestrel (M‐DG)
Study: 2147014
Drug: Monophasic preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monophasic preparation containing ethinylestradiol and gestodene (M‐GD)
Study: 2147014
Drug: Triphasic preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphasic preparation of ethinylestradiol and levonorgestrel (T‐LN)
Study: 17845881
Drug: Home-walking exercise
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home-walking exercise prescription
Study: 9391992
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (50 micrograms) biweekly
Study: 9391992
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (100 micrograms) biweekly
Study: 8934730
Drug: Bolus single
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus single agent 5-FU
Study: 30806758
Drug: IRI/CDDP (IRI,
Approvals — FDA: no, EMA: no, PMDA: no
Description: IRI/CDDP (IRI, 60 mg/m2; CDDP, 30 mg/m2, q2w)
Study: 30806758
Drug: IRI (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: IRI (150 mg/m2, q2w)
Study: 22176808
Drug: 20% mannitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% mannitol (1 g/kg)
Study: 22176808
Drug: 23.4% hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23.4% hypertonic saline (0.686 mL/kg)
Study: 19997098
Drug: Sublingual administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual administration of a single dose of testosterone
Study: 18996862
Drug: Experimental modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental modified starch therapy (100 g digestible starch)
Study: 18996862
Drug: Traditional uncooked
Normalized name: egg shell, cooked
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional uncooked cornstarch therapy (100 g)
Study: 7436551
Drug: Dihydroergotamine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergotamine and heparin (DHE‐heparin) medication (2500 IU sodium heparin and 0.5 mg DHE, both given subcutaneously twice daily)
Study: 7436551
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of heparin (5,000 IU of sodium heparin given subcutaneously thrice daily)
Study: 25398970
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist protocol (n = 42)
Study: 25398970
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist protocol (n = 41)
Study: 21373274
Drug: Self-testing of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-testing of vaginal pH using test gloves, twice a week from 12th to 32nd week of gestation.
Study: 20193613
Drug: Intranasal glucocorticoid
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal glucocorticoid (INGS) for one year
Study: 20193613
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy (SIT) for 4 weeks
Study: 17579637
Drug: 2500 mg
Normalized name: inulin 2500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2500 mg calcium diet
Study: 17579637
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg calcium diet
Study: 15514504
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (0.3 g x kg(‐1) with approximately 1 L of water)
Study: 3365983
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive use with alcohol consumption
Study: 3365983
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive use without alcohol consumption
Study: 23623526
Drug: Lansoprazole (detailed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (detailed dosage not provided)
Study: 18166096
Drug: Periodontal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal therapy provided by the study
Study: 12493134
Drug: Oral treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral treatments for type II diabetes
Study: 10742366
Drug: Theophylline (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (8 mg/kg)
Study: 29914524
Drug: Multi-year implementation
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-year implementation intervention for AOUD treatment delivery
Study: 29914524
Drug: Staff training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Staff training and funding for medications
Study: 24516879
Drug: 20 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μg calcifediol daily
Study: 24516879
Drug: 140 μg
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 140 μg calcifediol weekly
Study: 24516879
Drug: Single bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single bolus of 140 μg calcifediol
Study: 24516879
Drug: 20 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μg vitamin D3 daily
Study: 24516879
Drug: 140 μg
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 140 μg vitamin D3 weekly
Study: 24516879
Drug: Single bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single bolus of 140 μg vitamin D3
Study: 22456624
Drug: PEG 3
Normalized name: PEG 300
DrugBank: Polyethylene glycol 300 (DB11161)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG 3 L the day before and 1 L 3h before the procedure (split regimen)
Study: 22456624
Drug: PEG 4
Normalized name: PEG 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG 4 L the afternoon before colonoscopy (full regimen)
Study: 21047442
Drug: Guided web-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided web-based self-help intervention based on Problem Solving Treatment (PST) for 6 weeks
Study: 15208052
Drug: Mifepristone, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone, 100 mg/day for 2 consecutive days every 30 days, from months 2-7 of implant use
Study: 12126343
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy along with standard pharmacotherapy
Study: 7857352
Drug: Pidotimod 800
Normalized name: pidotimod
DrugBank: Pidotimod (DB11364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pidotimod 800 mg administered orally twice a day for 30 days
Study: 2510263
Drug: Sucralfate, 1
Normalized name: Sucralfate, 1 g oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate, 1 g t.i.d.
Study: 31750726
Drug: Vocal Music
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vocal Music Therapy (VMT) program for 12 weeks
Study: 26645517
Drug: Coenzyme Q(10)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coenzyme Q(10) 100 mg daily for 60 days
Study: 18031592
Drug: Mixed fibre
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed fibre dose (3 g Plantago ovata husk and 1 g glucomannan) twice daily (b.i.d.)
Study: 18031592
Drug: Mixed fibre
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed fibre dose (3 g Plantago ovata husk and 1 g glucomannan) three times daily (t.i.d.)
Study: 18031592
Drug: Mixed fibre
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed fibre dose (b.i.d. and t.i.d.)
Study: 15963388
Drug: glimepiride (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: glimepiride (1 to 6 mg)
Study: 12502980
Drug: PPIA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPIA plus 0.5 mg/kg oral midazolam
Study: 6849739
Drug: Atenolol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (25 mg oral)
Study: 6849739
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 mg and 50 mg oral)
Study: 6849739
Drug: Isoprenaline (sustained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoprenaline (sustained infusion)
Study: 31924318
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (Control, in diabetic patients)
Study: 29049282
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (information and referrals)
Study: 21946154
Drug: Protein-glucose solution
Normalized name: glucose Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-glucose solution (8% ¹³C‐enriched glucose and 2% milk protein concentrate)
Study: 21946154
Drug: Glucose only
Normalized name: Glucose only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose only solution
Study: 12631093
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (benazepril 10 mg/day + valsartan 80 mg/day)
Study: 12631093
Drug: Combined therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy, Benazepril, Valsartan
Study: 1353102
Drug: HIVAC-1e vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIVAC-1e vaccine
Study: 31044424
Drug: Noradrenaline (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenaline (5 μg)
Study: 25197807
Drug: Suvorexant 10
Normalized name: suvorexant 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suvorexant 10 mg, 20 mg, 40 mg, 80 mg
Study: 25197807
Drug: Gaboxadol 15
Normalized name: Gaboxadol
DrugBank: Gaboxadol (DB06554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gaboxadol 15 mg, Zolpidem 10 mg, Trazodone 150 mg
Study: 21868715
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate 150 mg twice daily on days 1 to 3 and once on day 4
Study: 21868715
Drug: Digoxin loading
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin loading dose of 0.5 mg on day 1 and 0.25 mg on days 2 to 4
Study: 17253134
Drug: mesalazine 1.6
Normalized name: Mesalazine 1.6 g gastro-resistant and prolonged-release oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: mesalazine 1.6 g/d (group A)